It alleviates symptoms and improves survival in a murine model of chronic relapsing-remitting experimental autoimmune encephalomyelitis (EAE) when administered at a dose of 20 μg; reduces inflammatory lesions and the number of infiltrating monocytes in the lumbar spinal cord of EAE mice; induces MCP-1 production in basophils (but not in mast cells); enhances NFAT activation in reporter assays via LMIR5; binds to CD1d in vitro; and promotes proliferation of isolated murine splenocytes.